DuBois, S. G., Granger, M. M., Groshen, S., Tsao-Wei, D., Ji, L., Shamirian, A., Czarnecki, S., Goodarzian, F., Berkovich, R., Shimada, H., Villablanca, J. G., Vo, K. T., Pinto, N., Mosse, Y. P., Maris, J. M., Shusterman, S., Cohn, S. L., Goldsmith, K. C., Weiss, B., Yanik, G. A., Twist, C. J., Irwin, M. S., Haas-Kogan, D. A., Park, J. R., Marachelian, A., & Matthay, K. K. (2021). randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of clinical oncology, 39(31), 3506–3514. http://access.bl.uk/ark:/81055/vdc_100150610215.0x00003e